Cancer Nanovaccines: Mechanisms, Design Principles, and Clinical Translation
Open Access
- 9 April 2025
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (17) , 16204-16223
Abstract
Cancer immunotherapy has transformed the landscape of oncological treatment by employing various strategies to teach the immune system to eliminate tumors. Among these, cancer nanovaccines are an emerging strategy that utilizes nanotechnology to enhance immune activation in response to tumor antigens. This review addresses the principles behind the different technologies in this field aimed at generating a robust and effective immune response. The diversity of strategies adopted for the design of nanovaccines is discussed, including the types of active agents, nanocarriers, their functionalizations, and the incorporation of adjuvants. Furthermore, strategies to optimize nanoparticle formulations to enhance the antigen presentation, target immune cells, and organs and promote strong and durable antitumor responses are explored. Finally, we analyze the current state of clinical application, highlighting ongoing clinical trials and the future potential of cancer nanovaccines. The insights presented in this review aim to guide future research and development efforts in the field, contributing to the advancement of more effective and targeted nanovaccines in the fight against cancer.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (440398/2022-3, 442690/2020-7)
- Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo (2020/00124-5, 2022/01434-3)
This publication has 184 references indexed in Scilit:
- DNA Vaccines: Developing New Strategies against CancerJournal of Biomedicine and Biotechnology, 2010
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 yearsHuman Vaccines, 2009
- Virus-Like Particles as a Vaccine Delivery System: Myths and Facts2009
- Pathogen Recognition and Innate ImmunityCell, 2006
- Interleukin‐10 suppression of myeloid cell activation — a continuing puzzleImmunology, 2004
- Immunotherapeutic uses of CpG oligodeoxynucleotidesNature Reviews Immunology, 2004
- Interleukin-12 and the regulation of innate resistance and adaptive immunityNature Reviews Immunology, 2003
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.Proceedings of the National Academy of Sciences, 1995
- Interleukin-4: a prototypic immunoregulatory lymphokine.1991